Genmab A (GMAB) Divestments (2018 - 2026)
Genmab A's (GMAB) quarterly Divestments came in at -$579.0 million in Q1 2021, down 6533.33% YoY from $9.0 million in Q1 2020, and down 22572999.42% on a QoQ basis from -$2565.0 in Q3 2020.
Genmab A (GMAB) Divestments (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has 4 years of Divestments data on file, last reported at -$579.0 million in Q1 2021.
- Quarterly Divestments fell 6533.33% year-over-year to -$579.0 million in Q1 2021, while the trailing twelve-month figure through Mar 2021 was -$570.0 million (down 26.21% YoY) and the FY2019 annual result came in at -$1983.0, up 100.0% from the prior year.
- Divestments fell to -$579.0 million in Q1 2021, from -$2565.0 in the prior quarter.
- In the past five years, Divestments ranged from a high of $9.0 million in Q1 2020 to a low of -$579.0 million in Q1 2021.
- A 4-year average of -$171.8 million and a median of -$23.1 million in 2019 frame the typical range for Divestments.
- Annual changes were most pronounced in 2019 — Divestments soared 100.0% — and 2021, when it plunged 6533.33%.
- Tracing GMAB's Divestments over 4 years: stood at -$414.4 million in 2018, then soared by 100.0% to -$46.0 in 2019, then sank by 5476.09% to -$2565.0 in 2020, then tumbled by 22572999.42% to -$579.0 million in 2021.
- The last three Divestments figures came in at -$579.0 million (Q1 2021), -$2565.0 (Q3 2020), and $9.0 million (Q1 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 9.82 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -13.21 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.00 Mn |
| Sep 30, 2025 | -3.00 Mn |
| Jun 30, 2025 | -3.00 Mn |
| Mar 31, 2025 | -1.00 Mn |
| Dec 31, 2024 | -8.00 Mn |
| Sep 30, 2024 | -5.00 Mn |
| Jun 30, 2024 | -5.00 Mn |
| Mar 31, 2024 | -3.00 Mn |
| Dec 31, 2023 | -4.00 Mn |
| Mar 31, 2021 | -579.00 Mn |
| Sep 30, 2020 | -2,565.00 |
| Mar 31, 2020 | 9.00 Mn |
| Dec 31, 2019 | -46.00 |
| Sep 30, 2019 | -46.24 Mn |
| Dec 31, 2018 | -414.40 Mn |